BTK and B-cell chronic lymphocytic leukemia: The currently approved BTK inhibitors for CLL treatment (ibrutinib, acalabrutinib, and zanubrutinib) all bind to the C481 site in BTK, thereby blocking its kinase activity [28,29,30].